公开(公告)号：EP3858867A1

公开(公告)日：2021-08-04

申请号：EP19867338.6

申请日：2019-09-26

申请人： Xiamen University ,  Xiamen Innovax Biotech Co., Ltd.

发明人： LI, Shaowei ,  WANG, Daning ,  CHEN, Jie ,  GU, Ying ,  ZHANG, Jun ,  XIA, Ningshao

IPC分类号： C07K19/00 ,  C12N15/62 ,  C12N15/63 ,  A61K39/295 ,  A61P31/20

摘要： Provided are a mutated HPV51 L1 protein or a variant thereof, a coding sequence thereof, a preparation method therefor, and a virus-like particle containing same, wherein the protein or the variant and the virus-like particle thereof are capable of inducing neutralizing antibodies against at least two types of HPV (for example, HPV51 and HPV69, or HPV51, HPV69 and HPV26). Also provided is the use of the above-mentioned protein and the virus-like particle for preparing a pharmaceutical composition or a vaccine, wherein the pharmaceutical composition or the vaccine can be used to prevent infections of the at least two types of HPV and diseases caused by the infections, such as cervical cancer and condyloma acuminatum.

公开(公告)号：EP3656854A1

公开(公告)日：2020-05-27

申请号：EP18835927.7

申请日：2018-07-18

申请人： Xiamen University ,  Yang Sheng Tang Company, Ltd.

发明人： CHENG, Tong ,  WANG, Wei ,  WAN, Junkai ,  FU, Wenkun ,  YE, Xiangzhong ,  ZHANG, Jun ,  XIA, Ningshao

IPC分类号： C12N7/00 ,  C12N15/11 ,  A61K35/76 ,  A61P35/00

摘要： Provided are an enterovirus D68 (EV-D68) or a modified form thereof, or a nucleic acid molecule comprising a genomic sequence or cDNA sequence of the EV-D68 or a modified form thereof, or a complementary sequence of the genomic sequence or cDNA sequence, or a pharmaceutical composition comprising the EV-D68 or a modified form thereof, or the nucleic acid molecule, and use of the EV-D68 or a modified form thereof, or the nucleic acid molecule in the manufacture of a pharmaceutical composition for treating a tumor.

公开(公告)号：EP3617317A1

公开(公告)日：2020-03-04

申请号：EP18754095.0

申请日：2018-02-05

申请人： Xiamen University ,  Yang Sheng Tang Company, Ltd.

发明人： ZHANG, Tianying ,  YUAN, Quan ,  GUO, Xueran ,  WEI, Minxi ,  KANG, Xiaozhen ,  ZHANG, Jun ,  XIA, Ningshao

IPC分类号： C12N15/51 ,  C12N15/62 ,  C07K14/02 ,  C07K19/00 ,  A61K39/29 ,  A61P31/12

摘要： The invention relates to a polypeptide carrier for presenting a target polypeptide, and use thereof. In particular, the invention relates to a nucleic acid molecule, comprising a nucleotide sequence encoding a polypeptide carrier, and being used for insertion of a nucleotide sequence encoding a target polypeptide. In addition, the invention further relates to a recombinant protein comprising the polypeptide carrier and a target polypeptide. Furthermore, the invention further relates to use of the nucleic acid molecule and the recombinant protein. In addition, the invention further relates to a vaccine or a pharmaceutical composition useful for preventing, alleviating or treating HBV infection or a disease associated with HBV infection (e.g., hepatitis B), comprising a recombinant protein comprising the polypeptide carrier of the invention and an epitope from HBV.

公开(公告)号：EP3594328A1

公开(公告)日：2020-01-15

申请号：EP18764074.3

申请日：2018-02-28

申请人： Xiamen University ,  Yang Sheng Tang Company, Ltd.

发明人： HUANG, Chenghao ,  LUO, Yong ,  YUAN, Quan ,  ZHANG, Jun ,  XIA, Ningshao

IPC分类号： C12N7/00 ,  C12N15/869 ,  C12N5/10 ,  A61K35/763 ,  A61P35/00

摘要： The invention relates to the field of virology and tumor therapy. In particular, the present invention provides a recombinant herpes simplex virus (HSV) capable of specifically replicating at a high level in a tumor cell and effectively killing the tumor cell, but replicating at low levels in normal cells, thereby the recombinant herpes simplex virus of the present invention not only has high lethality against tumor cells, but also has significantly decreased side effects (especially neurotoxicity). Further, the present invention relates to a viral vector constructed based on the recombinant herpes simplex virus, a pharmaceutical composition comprising the recombinant herpes simplex virus or the viral vector, and the use of the recombinant herpes simplex virus or the viral vector. The recombinant herpes simplex virus of the present invention can be used to infect and kill tumor cells, and can be used for gene drug delivery into tumor cells for gene therapy.

公开(公告)号：EP3299384A1

公开(公告)日：2018-03-28

申请号：EP16795912.1

申请日：2016-05-20

申请人： Xiamen University

发明人： GE, Shengxiang ,  LI, Tingdong ,  JIA, Lianzhi ,  LI, Yijian ,  XUE, Miaoge ,  ZENG, Yuanjun ,  ZHANG, Jun ,  XIA, Ningshao

IPC分类号： C07K14/14 ,  C12N15/46 ,  A61K39/15 ,  A61P31/14

CPC分类号： C07K14/005 ,  A61K39/12 ,  A61K39/15 ,  A61K2039/552 ,  A61K2039/55505 ,  A61K2039/575 ,  A61P1/00 ,  A61P1/12 ,  A61P29/00 ,  A61P31/14 ,  C12N7/00 ,  C12N2720/12322 ,  C12N2720/12334 ,  C12N2720/12351

摘要： The invention relates to a truncated rotavirus VP4 protein, a sequence encoding the same, a method for preparing the same, and a pharmaceutical composition and a vaccine comprising the protein, wherein the protein, the pharmaceutical composition and the vaccine are useful for preventing, alleviating or treating rotavirus infection and a disease caused by rotavirus infection, such as rotavirus gastroenteritis and diarrhea. The invention further relates to use of the protein in the manufacture of a pharmaceutical composition or a vaccine for preventing, alleviating or treating rotavirus infection and a disease caused by rotavirus infection, such as rotavirus gastroenteritis and diarrhea.

摘要翻译： 本发明涉及截短的轮状病毒VP4蛋白，编码它的序列，其制备方法，以及包含该蛋白的药物组合物和疫苗，其中该蛋白，该药物组合物和疫苗可用于预防，缓解 或治疗轮状病毒感染和轮状病毒感染引起的疾病，如轮状病毒胃肠炎和腹泻。 本发明进一步涉及该蛋白质在制备用于预防，减轻或治疗轮状病毒感染和由轮状病毒感染引起的疾病（例如轮状病毒胃肠炎和腹泻）的药物组合物或疫苗中的用途。

公开(公告)号：EP2716653B1

公开(公告)日：2017-04-19

申请号：EP12788749.5

申请日：2012-05-22

申请人： Xiamen University ,  Xiamen Innovax Biotech Co., Ltd.

发明人： LI, Shaowei ,  KONG, Xianglin ,  WEI, Minxi ,  PAN, Huirong ,  ZHANG, Jun ,  XIA, Ningshao

IPC分类号： C07K14/025 ,  C12N15/37 ,  C12N15/63 ,  C12N7/04 ,  C07K1/16 ,  C07K1/30 ,  A61K39/12 ,  A61P31/20 ,  A61P35/00

CPC分类号： C07K14/005 ,  A61K39/12 ,  A61K2039/5258 ,  A61K2039/55566 ,  C12N2710/20022 ,  C12N2710/20023 ,  C12N2710/20034

公开(公告)号：EP2174957B1

公开(公告)日：2016-03-16

申请号：EP08772961.2

申请日：2008-06-16

申请人： Xiamen University ,  Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.

发明人： CHEN, Yixin ,  LUO, Wenxin ,  ZHANG, Jun ,  XIA, Ningshao ,  GUAN, Yi ,  CHEN, Honglin

IPC分类号： C07K16/18 ,  G01N33/53 ,  G01N33/569 ,  A61K39/395 ,  C07K7/06

CPC分类号： C07K16/1018 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/622 ,  C07K2317/76 ,  C12N2760/16111 ,  G01N33/56983 ,  G01N2333/11

公开(公告)号：EP2860188A1

公开(公告)日：2015-04-15

申请号：EP13804161.1

申请日：2013-06-06

申请人： Xiamen University ,  Xiamen Innovax Biotech Co., Ltd.

发明人： YUAN, Quan ,  ZHANG, Tianying ,  LUO, Wenxin ,  CHEN, Yixin ,  ZHANG, Jun ,  XIA, Ningshao

IPC分类号： C07K14/02 ,  C07K16/28 ,  A61K39/29

摘要： The present invention relates to epitope peptides (or mutants thereof) for treating hepatitis B virus infection, recombinant proteins comprising such epitope peptides (or mutants thereof) and carrier proteins, and uses of such epitope peptides (or mutants thereof) and recombinant proteins. The present invention also relates to antibodies against such epitope peptides, cell lines producing said antibodies, and uses thereof. Furthermore, the present invention relates to vaccines or pharmaceutical compositons for treating or alleviating one or more symptoms associated with hepatitis B virus infection, which comprise the recombinant proteins or antibodies according to the invention, respectively.

摘要翻译： 本发明涉及表位肽（或其突变体），用于治疗乙型肝炎病毒感染，重组蛋白，其包含搜索表位肽（或其突变体）和载体蛋白，和搜索表位肽（或其突变体）和重组蛋白的用途。 因此，本发明涉及抗体针对寻求表位肽，细胞系产生所述抗体，及其用途。 进一步地，本发明涉及疫苗或用于治疗或缓解与乙型肝炎病毒感染相关的一种或多种症状，其包含分别gemäß到本发明，重组蛋白质或抗体的药物COMPOSITONS。

公开(公告)号：EP4434626A1

公开(公告)日：2024-09-25

申请号：EP22894720.6

申请日：2022-11-11

申请人： Xiamen University ,  Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. ,  Xiamen Innodx Biotech Co., Ltd

发明人： ZHANG, Dongxu ,  GAO, Runxin ,  HUANG, Shaolei ,  HUANG, Yulin ,  LIU, Guoqiang ,  YANG, Jiayu ,  ZENG, Juntian ,  SONG, Liuwei ,  GE, Shengxiang ,  ZHANG, Jun ,  XIA, Ningshao

IPC分类号： B01L3/00 ,  B01J19/00

CPC分类号： B01L3/00 ,  B01J19/00

摘要： The present disclosure relates to a microfluidic chip and a microfluidic chip detection system. The microfluidic chip including: a storage member provided with a groove therein, at least two storage chambers being disposed around the groove; a base disposed at one end of the storage member away from the groove, a reaction chamber being disposed on the base; and a valve disposed in the groove, the valve being configured to operatively communicate any one of the at least two storage chambers with the reaction chamber. The present disclosure can lead the solution in any storage chamber to the reaction chamber or lead the solution in the reaction chamber to any storage chamber by operating the valve, so that the solution transfer is realized, the structure is simple and compact, the length of the flow channels can be greatly shortened, and the detection efficiency is improved.

公开(公告)号：EP4174181A1

公开(公告)日：2023-05-03

申请号：EP21829053.4

申请日：2021-06-24

申请人： Xiamen University ,  Yang Sheng Tang Company, Ltd.

发明人： YUAN, Quan ,  CAO, Jiali ,  ZHANG, Yali ,  WANG, Mingfeng ,  MA, Jian ,  ZHANG, Tianying ,  ZHANG, Jun ,  XIA, Ningshao

IPC分类号： C12N15/52 ,  C12N15/36 ,  C12N15/867 ,  C12N15/65 ,  C12N5/10 ,  C12Q1/02 ,  C12Q1/66

摘要： The present invention belongs to the field of virology, in particular to the field of hepatitis B virus treatment. Provided are a model and a method for screening HBV cccDNA inhibitors. According to the screening model and the method, the detection of a split luciferase is used as an alternative index of HBV cccDNA detection, and a cccDNA-targeted drug can be screened in high throughput.